Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Ibrutinib is used:
to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of t he immune system) who have already been treated with at least one other chemotherapy medication,
Ibrutinib (PCI-32765) is a potent and highly selectiveBrutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.